Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 01, 2008. The report details a specific corporate action regarding the company's share capital executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes.
- Shares Purchased: 3,195,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,098.7972 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 8.97% of total voting rights).
- Shares in Issue: 5,284,347,049 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through a share buyback and subsequent cancellation. On July 01, 2008, GSK purchased 3,195,000 shares which were immediately cancelled. This action increased the proportion of Treasury shares held by the company to 8.97% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,284,347,049) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (8.97%).
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial results.